Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enfortumab vedotin plus pembrolizumab for unresectable urothelial carcinoma (phase II, single-arm, open-label)
jRCTs041250111Phase 2Recruiting
- Start
- Nov 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enfortumab vedotin and pembrolizumab in transitional cell carcinoma (TCC). Primary endpoint: objective response rate. Started Nov 2025; status: recruiting.
02
Drugs
enfortumab vedotinpembrolizumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on jRCTs041250111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041250111.